The trial was designed to evaluate the safety, tolerability and pharmacokinetics of low doses of ITI-007 in these patients. According to the company, secondary endpoints of the trial
The project will help the company keep pace with a growing demand for the development and use of biologics, which currently represents nearly 50% of its overall pipeline.
As part of the deal, Yabao will receive exclusive rights to discover, develop and commercialise new products in China, Taiwan and Hong Kong, while MRC Technology will retain
In the coming months, the European Commission (EC) is expected to make a final decision on granting marketing authorization for Cerdelga in the European Union (EU). In August,
Victoza (liraglutide) is a once-daily human the human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence 97% similar to endogenous human GLP-1. It works by stimulating the
The EMA committee’s positive opinion is based on pivotal data from the replicate Phase III INPULSIS trials which included about 1,066 patients from 24 countries. Results from these
Maternal immunization is a strategy to protect newborns through the transfer of maternal antibodies via active transport mechanisms in the placenta, thus providing the infant the benefit of
The new 120,000m² facility will provide increased capacity for compounds within the company’s immunology and oncology pipelines. The Singapore site includes a contained API facility, additional buildings and
Hysingla ER is a once-daily, single-entity medication formulated using the company’s extended-release solid oral platform, RESISTEC, which uses a combination of polymer and processing that confers tablet hardness
Dupilumab is indicated for AD patients who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate. It is an investigational therapy
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.